{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-333853","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2026-08-05T11:17:00+00:00","discovered_at":"2026-08-05T11:20:00.346446+00:00","generated_at":"2026-08-05T11:20:09.438191+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rapport Therapeutics Q2 net loss $56.6M; initiates RAP-219 Phase 3 in focal seizures","bullets":["Net loss $56.6M in Q2 2026 vs $26.7M in Q2 2025; R&D spend $51.4M (up from $22.7M).","Cash $436.1M at June 30, 2026, down from $476.8M at March 31; runway into H2 2029.","Phase 3 program for RAP-219 in focal onset seizures initiated (FOCUS 1 and FOCUS 2 enrolling).","Phase 2 bipolar mania trial topline results expected October 2026; RAP-219 half-life now 22 days.","IND approved in China for RAP-219 Phase 3 trials; RAP-641 IND-enabling activities continue."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-333853","json":"https://secwatch.observer/filing/0001193125-26-333853.json","markdown":"https://secwatch.observer/filing/0001193125-26-333853.md","text":"https://secwatch.observer/filing/0001193125-26-333853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/0001193125-26-333853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:20:09.438191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}